• 13 hours Silver Steadies Following Wild Week In Precious Metals Markets
  • 1 day $5 Million Gold Toilet Vanishes
  • 1 day Gold On The Rise After Fed Rate Cut
  • 1 day Oil Trader Loses $320 Million On Derivative Bets
  • 2 days S&P 500 Officially In An Earnings Recession
  • 2 days Miners Are Weathering The Trade War Storm
  • 3 days UK Credit Card Interest Rates Are Skyrocketing
  • 3 days From Frenzy To Flop, The Death Of This Year’s Most Hyped IPO
  • 3 days Are Smart TVs Spying On Us?
  • 4 days Is Fossil Fuel Divestment A Waste Of Time?
  • 4 days A Russian Billionaire’s Space Quest To Save Humanity
  • 4 days Markets Take Breather As Consolidation Continues
  • 4 days Economic Woes Weigh On Copper Prices
  • 5 days World's Largest IPO At Risk Following Drone Strikes
  • 5 days Gold Is Beating Buffett’s Berkshire Hathaway
  • 5 days What’s Behind The Silver Sell-Off?
  • 5 days The Retail Apocalypse Is Accelerating
  • 6 days The Top Tech Stocks Of The Year
  • 6 days America’s Workforce Elderly Workforce To Double By 2028
  • 6 days Toyota Tests Solar-Powered Prius
The Top Tech Stocks Of The Year

The Top Tech Stocks Of The Year

The tech bubble is far…

Gold Is Beating Buffett’s Berkshire Hathaway

Gold Is Beating Buffett’s Berkshire Hathaway

For the 20-year period, gold…

The Retail Apocalypse Is Accelerating

The Retail Apocalypse Is Accelerating

As the economy cycles down…

Tom Kool

Tom Kool

Writer, Safehaven.com

Tom majored in International Business at Amsterdam’s Higher School of Economics, he is now working as news editor for Oilprice.com and Safehaven.com

Contact Author

  1. Home
  2. News
  3. Breaking News

Anti-Aging Market To Hit $55 Billion

Anti-Aging

It’s not just you who’s aging. Our world is getting old. By next year, 55-year-olds will outnumber 5-year-olds. By 2050, the number of people aged 50 and older will rise to 3.2 billion--a twofold increase since 2015.

Baby Boomers, born between 1944 and 1964, are now desperately searching for the “fountain of youth”, and the market is finally responding.

The anti-aging market is believed to be one of the fastest-growing market segments in existence. Last year, the Global Anti-Aging Market was worth $42.5 billion, and estimates are that it will reach $55.03 billion by 2023.

Aside from the “traditional” anti-aging products, there has also been a dramatic rise in the number of companies offering various treatments and products of a more extreme nature. Few of them are approved by the Federal Drug Administration (FDA).

But the potentially most exciting part is this: Scientists now believe it may be possible to reverse a person's biological age with a combination of drugs and growth hormones. The prospects are still far away, but there has been enough movement to make the anti-aging market’s mouth water:

A small, one-year clinical trial published in the Aging Cell journal, has suggested for the first time that it might be possible to reverse the biological age.

In the trial, led by immunologist Gregory Fahy, the chief scientific officer and co-founder of Intervene Immune, nine participants aged 51 to 65 were given a combination of growth hormone and two types of diabetes medications during the study.  On average, their biological ages were reduced by an average of 2.5 years.  Related: Are Investors Being Lulled Into A False Sense Of Security?

The researchers spent a year running the Thymus Regeneration, Immunorestoration and Insulin Mitigation (TRIIM) trials.

Initially, the trial was meant to test whether a growth hormone and drug combination could be used safely in humans to restore thymic function lost due to aging.

Apparently, even the scientists who worked on the study were surprised by the much more dramatic results.

Geneticist Steve Horvath at the University of California, who conducted the study, told Nature magazine: "I'd expected to see slowing down of the clock, but not a reversal. That felt kind of futuristic."

Still, researchers caution that the findings are only preliminary because the trial was small and did not include a control arm. But there is no doubt that many companies will cling onto the trial results and various “miraculous” products will hit the market.

It’s happened before.

Earlier this year, the FDA issued a warning that plasma infusions from young people provide no proven clinical benefit against normal aging and a handful of illnesses, as promised by the companies selling it. They all were citing several studies claiming this to be true, despite the fact that tests were only conducted on mice. Nothing stopped the product from hitting the market because of the frenzy to reverse aging.   

Even though the FDA statement didn't call out any companies by name, it was clearly targeting the best-known among these—California-based Ambrosia Medical, which since 2017, has been selling its ‘anti-aging” treatment for $8,000 for one liter of blood and $12,000 for two

Following the agency’s warning, the company ceased patient treatments but others out there have not felt the need in this hungry market.

A company called Elysium Health is one. It’s managed to convince Nobel Prize winners to help sell its $50/month supplement promoting “longevity”.

And last year, a former Florida-based mortician and doctor announced the launch of a clinical trial giving participants blood infusions from young donors for a modest $285,000 “enrollment” fee. Related: Insurance Businesses Are Fleeing The UK In Droves

Even the big dogs are toying with the idea.

Google’s parent company, Alphabet, has invested heavily in its secretive anti-aging spinout called Calico.

Celularity, a biotech giant Celgene spinoff, raised $250 million last year to try to use postpartum placentas to delay the aging process.

But from the FDA’s perspective, this is the 21st-century snake oil—and none of it has been proven. We’ll see what it says when the latest journal study inching towards biological age reversal starts inspiring more marketers.

By Tom Kool for Safehaven.com

More Top Reads From Safehaven.com:

Back to homepage

Leave a comment

Leave a comment